Compare ADMA Biologics Inc (ADMA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Invesco NASDAQ 100 ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Invesco NASDAQ 100 ETF trades at $297.64. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QQQM | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $307.23 |
52-Week Low | $7.60 | $229.87 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
QQQM, tracking the Nasdaq-100, trades at $298.55, up 0.59% with a bullish technical signal from moving averages. The ETF benefits from lower fees compared to QQQ, attracting cost-conscious investors. Recent news highlights its inclusion in retirement portfolios and strong inflows into Nasdaq-focused ETFs, supported by tech sector performance.
Outlook remains positive due to tech-led growth, but risks include market volatility and concentration in mega-cap stocks. The ETF offers exposure to high-growth companies, with institutional activity showing mixed signals, such as Bank of America reducing its position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
